Multiple Myeloma Management in 2020

EP. 1: Treatment for High-Risk Asymptomatic Myeloma

January 29th 2020

EP. 2: Emerging Regimens for Smoldering Myeloma

January 29th 2020

EP. 3: Induction Therapy for Myeloma

January 29th 2020

EP. 4: Initial Therapy for High-Risk Myeloma

January 29th 2020

EP. 5: Transplant-Eligible Multiple Myeloma

January 29th 2020

EP. 6: MRD as a Composite End Point in Myeloma

January 29th 2020

EP. 7: Outcomes With Transplant in Myeloma

January 29th 2020

EP. 8: CD38-Targeted Monoclonal Antibodies in Myeloma

January 29th 2020

EP. 9: Choosing Front-Line Therapy for Myeloma

January 29th 2020

EP. 10: Nuances of Using Frontline Daratumumab for Myeloma

January 29th 2020

EP. 11: Considering Daratumumab-Based Quadruplets for Myeloma

January 29th 2020

EP. 12: Maintenance Therapy for Multiple Myeloma

January 29th 2020

EP. 13: Outcomes for Relapsed/Refractory Myeloma

January 29th 2020

EP. 14: Treatment Options for Lenalidomide-Refractory Myeloma

January 29th 2020

EP. 15: Coming Soon: Isatuximab + Pom/Dex for Relapsed Myeloma

January 29th 2020

EP. 16: BCMA-Targeted Approaches for Relapsed Myeloma

January 29th 2020

EP. 17: Real-World Use of BCMA-Targeted Therapy in Myeloma

January 29th 2020